1. Home
  2. EXFY vs OTLK Comparison

EXFY vs OTLK Comparison

Compare EXFY & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

SELL

Current Price

$2.45

Market Cap

217.0M

Sector

Technology

ML Signal

SELL

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

SELL

Current Price

$0.57

Market Cap

249.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EXFY
OTLK
Founded
2008
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
217.0M
249.6M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
EXFY
OTLK
Price
$2.45
$0.57
Analyst Decision
Hold
Buy
Analyst Count
3
4
Target Price
$2.83
★ $5.03
AVG Volume (30 Days)
455.0K
★ 3.5M
Earning Date
11-05-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 55.91
EPS
★ N/A
N/A
Revenue
★ $142,101,000.00
$8,146,123.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.15
$6,355.64
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 2.06
N/A
52 Week Low
$0.69
$0.16
52 Week High
$2.81
$2.54

Technical Indicators

Market Signals
Indicator
EXFY
OTLK
Relative Strength Index (RSI) 57.97 35.64
Support Level $2.05 $0.52
Resistance Level $2.80 $0.70
Average True Range (ATR) 0.11 0.04
MACD 0.02 0.00
Stochastic Oscillator 95.18 25.27

Price Performance

Historical Comparison
EXFY
OTLK

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: